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to-voxel mapping between the initial planning scan and the 
treatment scan. Therefore, deformation maps can be applied 
to propagate contours from planning CT to daily images, but 
also to compute dose distribution from the deformed images 
for dose accumulation purpose.  
In this presentation, we will describe the general framework 
of deformable image registration, and will cover the main 
class-solutions for registration-based recontouring according 
to the tumor location and the available imaging modality, 
i.e. kV- or MV/CB-CT. Typical adaptive workflows based on 
deformable registration will be presented, as well as their 
advantages and potential limitations. Last, we will emphasize 
the essential role of the operator for accuracy and 
consistency check of the deformed contours, any inaccuracy 
in this step necessarily introducing systematic errors in the 
planning process.  
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In the Erasmus MC radiotherapy department, atlas-based 
auto-segmentation of both clinical target volumes and organs 
at risk (OARs) is an important time-saving tool in daily clinical 
routine to assist both physicians and technicians. The 
accuracy of delineations has become increasingly important 
due to enhanced conformality of dose distributions as 
realized by IMRT and VMAT, and the use of reduced PTV 
margins in combination with image guidance. Clinical 
validation of atlas-based auto-segmentation for head-and-
neck patients showed a reduction of hands-on time for 
delineation from 180 to 66 minutes, where structures were 
evaluated as ‘minor-deviations, editable’ or better (D. Teguh 
; Int. J. Radiation Oncology Biol. Phys., Vol. 81, No. 4, pp. 
950–957, 2011). The influence of geometric differences 
between autocontours and manual delineations by different 
observers on the dosimetric impact can differ for CTV and for 
OAR (Voet PW, Radiother. Oncol. 2011 Mar;98(3):373-7). We 
clinically implemented Admire (Elekta AB, Sweden) as part of 
our workflow in 2010. In this workflow, critical review and 
editing of the autocontours is still relevant.  
For several target sites, a database was created containing 
fully contoured reference CT data sets (atlases). Depending 
on the tumor site, one or more atlases are used as an input 
for the generation of the patient-specific delineation (using 
the staple algorithm). The strategy of a single atlas can 
particularly be useful in case of adaptive treatments, 
resulting in a quick and more accurate autocontouring using 
the original delineated patient CT as the only atlas. An 
overview of the clinical implementation of Admire with 
regard to several tumor sites and the relation to treatment 
techniques such as breath-hold will be presented. 
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Purpose or Objective: Preoperative level of CA 19-9 
(prCA19.9) predicts survival of patients (pts) undergoing 
surgery for pancreatic adenocarcinoma (PAC). Actually, there 
is no evidence of using prCA19.9 as a marker customizing and 
modulating effectiveness of adjuvant treatment or predicting 
pattern of failure. Therefore, the purpose of this pooled 
analysis was to determine whether prCA19.9 could predict 
overall survival (OS), local control (LC), disease metastasis 
free survival (DMFS) and evaluate effectiveness of adjuvant 
therapies in a broad population. 
 
Material and Methods: We performed a multicenter 
retrospective analysis of 1122 patients (pts) who underwent 
surgical resection +/- adjuvant treatment [chemotherapy 
(aCT), radiotherapy +/- concomitant CT (RCT)] for PAC 
between 2000 and 2014 from 8 different institutions. Among 
700 pts with prCA19.9 value we applied the Kaplan-Meier 
method and the log-rank test to investigate differences in 
OS, LC, DMFS between defined groups based on: clinical and 
pathological factors, 4 prCA19.9 cutoff (5, 37, 100, 353) and 
5 relative prCa19.9 classes (0.0-5.0, 5.1-37.0, 37.1-100, 
100.1-353.0, >353.1). We fitted Weibull regression model 
with shared frailty on institution to identify independent 
predictors of OS using data from 404 pts with complete 
information. We applied a backward stepwise strategy to 
select the covariates, forcing CRT and RT in the final model. 
 
Results: Median follow-up (FU) was 27 months (2-225). At 
univariate analysis there was a strong impact of prCA19.9 
classes (0.0-5.0, 5.1-37.0, 37.1-100, 100.1-353.0, >353.1) on 
5-years OS (5.7% vs 37.9 vs 27.1 vs 17.4 vs 10.9, p< 0.001, 
Figure 1), 5-years LC (47.2% vs 63.3% vs 59.4% vs 43.4% vs 
50.2%, p= 0.008), 5-years DMFS (17.0% vs 46.0% vs 39.0% vs 
26.7 vs 23.4, p<0.001), respectively. Only in pts with prCA 
19.9 > 353.1 U/ml aCT had positive impact on 5-year OS 
(47.4% in pts treated with aCT vs 30.2% in pts not treated 
with aCT, p= 0.006). At multivariable model, sub-analysis of 
404 pts showed (Table 1): worse OS for grading 3 tumor (HR: 
1.85 95%CI 1.26-2.70, p= 0.002) tumor diameter > 30 mm 
(HR: 1.85, 95%CI: 1.35-2.53, p< 0.001), and better OS for pts 
treated with RCT doses > 50 Gy (HR: 0.38, 95%CI: 0.23-0.63, 
p< 0.001). Median OS worsened in pts with prCA19.9 >100 and 
<353 (HR: 1.77, 95%CI: 1.23-2.56, p= 0.002) and in pts with 
prCA19.9 ≥353.1 (HR: 1.92, 95%CI: 1.34-2.76, p<0.001). 
 





Conclusion: PrCA19.9 was a marker predicting OS and 
pattern of failure. ACT had positive impact on 5-year OS in 
pts with prCA19.9 > 353.1 U/ml. Our results suggest that 
prCA19-9 should be included in predictive models in order to 
customize treatments basing on prognostic factors of 
individual pts. Innovative treatments should be tested 
especially in pts with high prCA19.9 value. 
 
PV-0119  
Pattern of regional recurrence in adenocarcinoma of GEJ: 
implication for target delineation 
J. Zhang
1Cancer Hospital- CAMS, Radiation Oncology, Beijing, China 
1, J. Jin1, X. Wang1 
 
Purpose or Objective: To investigated the frequency and 
location of regional recurrence of locally advanced 
adenocarcinoma of GEJ patients after curative resection and 
refine the clinical target volume (CTV) delineation of 
radiotherapy. 
 
Material and Methods: From 2009 to 2013, we 
retrospectively reviewed 1140 esophagogastric cancer 
patients treated in our institute. Patients who had curative 
resection, and were histopathologically diagnosed with 
locally advanced adenocarcinoma of GEJ (T3/4 or any N+) 
and confirmed of regional recurrence in follow-up CT images 
were selected into the analysis. First regional recurrence was 
recorded and one diagnostic radiologist with specialty of 
gastrointestinal tract investigated. The frequency and 
location of regional failure at each node station were 
analyzed according to Siewert types. Reference CT images 
was obtained from a healthy volunteer. We then delineated 
the epicenters of recurrence sites at the equivalent location, 
based on the same vessels of reference CT images compared 
with the recurrence CT images on Pinnacle treatment 
planning system. The combined contour of all recurrence 
sites was presented on a digitally reconstructed radiograph 
(DRR) image.  
 
Results: Regional recurrence was identified in 78 patients. 
The majority of recurrence occurred within 2 years of follow-
up (Median, 10.9 months). Of all, 35 (44.9%) patients were 
regional nodule failure (NF) only, 24 (38%) experienced 
regional NF simultaneous with distant failure, 11 (14.1%) 
were locoregional, and 8 (10.3%) had concurrent distant and 
locoreginal failure. The most common recurrent lymph nodes 
station were No.16 (62.8%), No. 9 (32.1%), No. 11 (24.4%), 
No. 8 (17.9%), No. 7 (16.7%), No. 112 (12.8%), No. 4 (12.8%) 
and No. 12 (10.3%), respectively. 11 patients (14.1%) had 
recurrence at mediastinal lymph nodes. There was significant 
difference of NF in No. 9 (42.2% vs 18.2%, P=0.027) between 
Siewert type II and III AEG, but no difference was observed in 
the other node stations. Different frequency and location of 
regional recurrence were shown by CT and digitally 
reconstructed radiograph (DRR) images. A three-dimensional 
(3D) atlas based on vessel delineation and distribution of 
regional recurrence was established. 
 
Conclusion: The most prevalent nodal recurrence in patients 
with adenocarcinoma of GEJ after curative resection was 
along the abdominal aorta, celiac artery and splenic artery. 
Our findings suggest a modified elective lymphatic nodal 
target volume for IMRT contours in those patients.  
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Purpose or Objective: Concerns have been raised regarding 
the toxicity of neoadjuvant chemoradiotherapy (nCRT) for 
esophageal cancer that could contribute to an increased risk 
of complications after subsequent esophagectomy such as 
anastomotic leakage. In this respect, radiation dose to the 
gastric fundus is of interest as this part of the stomach is 
used for the esophagogastric anastomosis after 
esophagectomy. The aim of this study was to determine the 
influence of neoadjuvant radiation dose to the gastric fundus 
on the risk of postoperative anastomotic leakage in patients 
with esophageal cancer undergoing nCRT followed by 
transthoracic esophagectomy. 
 
Material and Methods: Between 2012 and 2015, 97 
consecutive patients with esophageal cancer who underwent 
nCRT followed by transthoracic esophagectomy with cervical 
anastomosis were analyzed. The nCRT regimen consisted of a 
total radiation dose of 41.4 Gy in 23 fractions of 1.8 Gy in 5 
weeks combined with weekly intravenous administration of 
carboplatin and paclitaxel. The gastric fundus was 
retrospectively contoured on the pre-treatment planning CT. 
Within this contour, dose-volume histogram parameters were 
calculated and univariable and multivariable logistic 
regression analyses were used to determine their influence 
on the risk of anastomotic leakage.  
 
Results: In 25 patients (26%) anastomotic leakage occurred. 
The mean radiation dose to the gastric fundus was 
significantly higher in patients with versus without 
anastomotic leakage (median [interquartile range]: 35.6 Gy 
[20.2-39.9] versus 24.9 Gy [11.9-35.1], respectively; p=0.047, 
Table 1). A mean dose above versus below 31.4 Gy was 
associated with leakage rates of 43% versus 15%, 
respectively. Two typical examples of dose distributions in 
relation to the gastric fundus in patients with and without 
anastomotic leakage are depicted in Figure 1. Adjusted for 
potential confounders including tumor location, clinical T-
stage and radiation modality, the mean radiation dose to the 
gastric fundus remained significantly and independently 
associated with an increased risk of anastomotic leakage in 
multivariable analysis (adjusted odds ratio 1.05 per 1 Gy 
increase, 95% confidence interval: 1.003-1.10, p=0.035). 
Also, in patients with anastomotic leakage the minimum 
radiation dose, V25, V30, and V35 to the gastric fundus were 
significantly higher (Table 1).  
 
